All In Biotech

NDA 215341 · Bayer Hlthcare

Kerendia

Finerenone · Oral · Nonsteroidal Mineralocorticoid-Receptor Antagonist

NovelPriority review

CDER novel approval, Jul 9, 2021: To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 9, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

83

22 Phase 3, 28 recruiting

FAERS reports

3,299

2,292 serious, 253 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 21, 2026.

Kerendia is indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM) [see Clinical Studies (14.1) ] . reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM) [see Clinical Studies (14.2) ] . reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% [see Clinical Studies (14.3) ] . Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM). ( 1 ) reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM). ( 1 ) reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. ( 1 )

Mechanism: Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. MR overactivation is thought to contribute to fibrosis and inflammation. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors.

Therapeutic areas: Cardiovascular and metabolic · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 16, 2026 Supplement 11 · Efficacy · priority review LetterLabel
  • Jul 11, 2025 Supplement 9 · Efficacy · priority review LabelLetter
  • Sep 1, 2022 Supplement 1 · Efficacy LetterLabel
  • Jul 9, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • KERENDIA · FINERENONE 20MG · TABLET, ORAL · Prescription
  • KERENDIA · FINERENONE 40MG · TABLET, ORAL · Prescription
  • KERENDIA · FINERENONE 10MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Finerenone" as an intervention, any sponsor and status, largest first.

All 83 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • glomerular filtration rate decreased335
  • hyperkalaemia283
  • blood creatinine increased246
  • death202
  • blood potassium increased197
  • renal impairment158
  • dizziness124
  • acute kidney injury116
  • suspected off label use107
  • diarrhoea106
  • nausea106
  • off label use96

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20171
202156
2022393
2023531
2024634
2025811
2026872

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kerendia (Finerenone)

2024 spending

$396M

Beneficiaries

88,208

403,577 claims

Per beneficiary

$4,493

$21.06 per unit

View as table
YearSpending
2020$0
2021$2,849,278
2022$74,078,624
2023$269,681,549
2024$396,302,773

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 176 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.